CNS Pharma partners with MD Anderson

By The Science Advisory Board staff writers

May 29, 2020 -- Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to investigate cancer treatment technologies.

The partnership will study a new class of antitumor agents, including lead anticancer drug candidate WP1244. The new drug candidate can cross the blood-brain barrier and is a DNA binding agent more potent than daunorubicin, a clinical chemotherapeutic agent used to prevent tumor cell growth. The biologic is of a novel class of DNA binding agents and was designed at MD Anderson using modular drug design strategies.

Dr. Waldemar Priebe, founder of CNS and a professor of medicinal chemistry at MD Anderson, will serve as the project's principal investigator. The partnership aligns with MD Anderson's conflict of interest policies, according to CNS.

EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.
Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...
AGC Biologics, Faron to manufacture cancer immunotherapy
Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.
Trio, Ajinomoto to develop cancer therapeutic
Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have...
Researchers reveal vulnerabilities of 'addicted' cancer cells
New findings about the mechanism by which some cancer cells can become "addicted" to glucose could lead to fresh approaches to targeted cancer therapies....

Copyright © 2020 scienceboard.net


Conferences
Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter